Brent L. Saunders
CEO and Chair at Bausch + Lomb Corporation
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 3 boards, counting each seat separately. Longest: Bausch + Lomb Corporation, 3 years.
Chief executive roles
Outstanding · grade A
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 81
10.6% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Bausch + Lomb Corporation May 20, 202698.7%
-
ARS Pharmaceuticals Inc. June 25, 202582.7%
-
Bausch + Lomb Corporation May 21, 202599.4%
-
Bausch + Lomb Corporation May 29, 2024100.0%
-
Bausch + Lomb Corporation April 24, 202399.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 5, 2026 | Bausch + Lomb Corporation | Shares withheld for tax | −4,231 | $16.76 | $70,912 |
| Aug 5, 2026 | Bausch + Lomb Corporation | Grant or award | +281,879 | — | — |
| May 22, 2026 | Bausch + Lomb Corporation | Shares withheld for tax | −2,886 | $15.92 | $45,945 |
| Mar 6, 2026 | Bausch + Lomb Corporation | Open-market purchase | +14,700 | $17.14 | $251,958 |
| Mar 6, 2026 | Bausch + Lomb Corporation | Grant or award | +14,700 | — | — |
| Feb 27, 2026 | Bausch + Lomb Corporation | Shares withheld for tax | −24,649 | $18.30 | $451,077 |
| Feb 26, 2026 | Bausch + Lomb Corporation | Shares withheld for tax | −22,059 | $18.49 | $407,871 |
| Feb 25, 2026 | Bausch + Lomb Corporation | Grant or award | +327,102 | — | — |
| Feb 23, 2026 | Bausch + Lomb Corporation | Shares withheld for tax | −65,444 | $17.99 | $1,177,338 |
| Aug 5, 2025 | Bausch + Lomb Corporation | Shares withheld for tax | −4,231 | $14.44 | $61,096 |
| Jun 16, 2025 | SkinHealth Systems Inc. | Grant or award | +73,051 | — | — |
| May 22, 2025 | Bausch + Lomb Corporation | Open-market purchase | +22,000 | $11.28 | $248,160 |
| May 22, 2025 | Bausch + Lomb Corporation | Grant or award | +22,000 | — | — |
| May 20, 2025 | ARS Pharmaceuticals Inc. | Option exercise | +120,000 | $1.01 | $121,200 |
| May 20, 2025 | ARS Pharmaceuticals Inc. | Open-market sale | −120,000 | $14.25 | $1,710,000 |
Questions about Brent L. Saunders
What boards is Brent L. Saunders on?
Brent L. Saunders sits on the boards of ARS Pharmaceuticals Inc., Bausch + Lomb Corporation and SkinHealth Systems Inc.
What company is Brent L. Saunders the CEO of?
Brent L. Saunders has been CEO and Chair of Bausch + Lomb Corporation since March 2023.
How long has Brent L. Saunders served on boards?
Our records show at least 11 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.